Product Description
Sun Pharma was developing sparc-147709, an injection agent for Multiple Myeloma. (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT00863174)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sun Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00863174 |
DOX_21_1477_09 | P1 |
Completed |
Multiple Myeloma |
2011-01-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|